Abstract
Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (inTandem1)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have